Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176239 · ClinicalTrials.gov registry record
Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting
A clinical trial of Primary Immunodeficiency Disease (PIDD), sponsored by BriovaRx Infusion Services.
- Completed
- Registry status
- 20
- Enrollment target
- 4
- Study locations
NCT02176239: Completed study of Primary Immunodeficiency Disease (PIDD), sponsored by BriovaRx Infusion Services.
NCT02176239 is a study of Primary Immunodeficiency Disease (PIDD) that has completed, run by BriovaRx Infusion Services. The registered enrollment target is 20 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02176239, a study of Primary Immunodeficiency Disease (PIDD), has completed, sponsored by BriovaRx Infusion Services.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments using CareExchange in the home setting.
Conditions Studied
Study Locations (4)
California
- Hoag Medical Group (In Alliance with St. Joseph Heritage Healthcare) - Newport Beach
Colorado
- IMMUNEOe International Research Centers - Centennial
Georgia
- Atlanta ENT - Atlanta
Kansas
- AxelaCare Health Solutions, LLC - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06 |
| Est. Completion | 2019-08 |
What the finished NCT02176239 record still lists
NCT02176239 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 1 condition, with Primary Immunodeficiency Disease (PIDD) appearing as the primary indexed condition, and to 0 interventions.
NCT02176239 reports a single indexed study location in California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT02176239 about?
NCT02176239 is a clinical study titled "Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting". The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments us...
What is the current status of trial NCT02176239?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2014-06. Estimated completion is 2019-08.
What conditions does trial NCT02176239 study?
This clinical trial studies the following conditions: Primary Immunodeficiency Disease (PIDD).
Who is sponsoring clinical trial NCT02176239?
This trial is sponsored by BriovaRx Infusion Services, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02176239 being conducted?
This trial has 4 study locations across California, Colorado, Georgia, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia